Artelo Biosciences ARTL Income Statement (2014-2025)

NASDAQ ARTL
$5.98 -0.21 (-3.39%)
At close: Sep 9, 2026 · 4:00 PM EDT
Reported Financials

Artelo Biosciences Quarterly Income Statement

Periods 47 quarters
Latest Dec 2025

Artelo Biosciences reported net income of -$4.16M for the quarter ended Dec 2025. This income statement covers 47 quarters of results from May 2014 through Dec 2025, standardized by Business Quant from the company’s SEC filings.

Income Statement May2014 Aug2014 Nov2014 Feb2015 May2015 Aug2015 Nov2015 Feb2016 May2016 Aug2016 Nov2016 Feb2017 May2017 Aug2017 Nov2017 Feb2018 May2018 Aug2018 Nov2018 Feb2019 May2019 Aug2019 Nov2019 Feb2020 May2020 Aug2020 Nov2020 Feb2021 May2021 Aug2021 Nov2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025
Operating items
Depreciation & Amortization - TotalDep. & Amort. (Tot)
62.00
Research & DevelopmentR&D
0.66M0.95M1.27M0.46M1.06M1.08M1.73M1.24M0.75M1.58M2.12M1.51M1.69M0.33M2.48M1.38M1.87M1.27M0.89M
Selling, General & AdministrativeSG&A
1.01M1.07M1.28M1.48M1.42M1.32M1.75M1.06M1.03M1.03M1.12M1.08M0.83M0.87M1.34M0.99M1.28M1.81M1.89M
Restructuring CostsRestructuring
0.31M0.30M0.33M0.37M0.32M0.25M0.33M0.31M
Other Operating ExpensesOther Opex
0.20M0.23M-0.31M-0.30M-0.33M-0.37M-0.32M-0.25M-0.33M-0.31M
Operating ExpensesOpex
1.87M2.25M2.55M1.95M2.47M2.39M3.48M2.29M1.78M2.61M3.24M2.59M2.51M1.20M3.81M2.38M3.15M3.09M2.79M
Operating IncomeOp. Inc
-1.87M-2.25M-2.55M-1.95M-2.47M-2.39M-3.48M-2.29M-1.78M-2.61M-3.24M-2.59M-2.51M-1.20M-3.81M-2.38M-3.15M-3.09M-2.79M
EBIT
-1.87M-2.25M-2.55M-1.95M-2.47M-2.39M-3.48M-2.29M-1.78M-2.61M-3.24M-2.59M-2.51M-1.20M-3.81M-2.38M-3.15M-3.09M-2.79M
Non-operating items
Non Operating Interest Expenses
0.01M0.07M0.11M0.01M
Non Operating Investment IncomeNon-Op. Investment Inc.
0.00M984.000.07M0.14M0.12M0.18M0.17M0.17M0.11M0.08M0.06M-0.25M
Interest & Investment IncomeInt & Inv Inc
253.00636.000.00M0.00M0.00M0.01M0.00M0.01M
Other Non Operating IncomeOther Non Op Inc.
0.00M0.00M0.07M-0.90M
Non Operating IncomeNon Op. Inc.
-0.00M0.00M-0.02M0.02M0.06M0.14M0.12M0.18M0.17M0.17M0.11M0.08M0.06M0.03M0.01M-0.07M-0.03M-1.38M
Net income details
EBT
-1.87M-2.25M-2.55M-1.95M-2.47M-2.40M-3.48M-2.29M-1.78M-2.61M-3.24M-2.59M-2.51M-1.20M-3.81M-2.37M-3.22M-3.19M-2.80M
Tax ProvisionsTaxes
-0.05M
Profit After TaxPAT
-1.87M-2.25M-2.59M-1.97M-2.45M-2.54M-3.21M-2.17M-1.60M-2.45M-3.07M-2.48M-2.43M-1.15M-3.76M-2.37M-3.22M-3.12M-4.16M
Income from Continuing OperationsIncome (Continuing)
-1.87M-2.25M-2.55M-1.90M-2.47M-2.40M-3.48M-2.29M-1.78M-2.61M-3.24M-2.59M-2.51M-1.20M-3.81M-2.37M-3.22M-3.19M-2.80M
Consolidated Net IncomeConsol Net Inc.
-1.87M-2.25M-2.55M-1.90M-2.47M-2.40M-3.48M-2.29M-1.78M-2.61M-3.24M-2.59M-2.51M-1.20M-3.81M-2.37M-3.22M-3.19M-2.80M
Income towards Parent CompanyParent Net Inc
-1.87M-2.25M-2.55M-1.90M-2.47M-2.40M-3.48M-2.29M-1.78M-2.61M-3.24M-2.59M-2.51M-1.20M-3.81M-2.37M-3.22M-3.19M-2.80M
Net Income towards Common StockholdersNet Income
-1.87M-2.25M-2.55M-1.90M-2.47M-2.40M-3.48M-2.29M-1.78M-2.61M-3.24M-2.59M-2.51M-1.20M-3.81M-2.37M-3.22M-3.19M-2.80M
Additional items
EPS (Basic)
-267.09-236.65-0.20-109.08-141.36-136.41-198.76-130.01-101.19-143.59-177.32-131.19-126.07-59.97-191.31-119.04-161.65-160.34-140.37
EPS (Diluted)
-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-143.59-177.32-131.19-126.07-59.97-191.61-117.12-151.51-109.61-73.39
Shares Outstanding
0.01M0.01M0.01M12.53M0.02M0.02M0.02M0.02M0.02M0.02M0.02M0.02M0.02M0.02M0.02M0.02M0.02M0.02M0.02M0.02M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
0.00M0.00M0.00M0.00M0.00M0.00M0.00M0.00M0.00M0.00M0.02M0.02M0.02M0.02M0.02M0.02M0.02M0.02M0.03M0.04M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
0.01M0.01M0.01M12.53M0.02M0.02M0.02M0.02M0.02M0.02M0.02M0.02M0.02M0.02M
EBITDA
-1.87M-2.25M-2.55M-1.95M-2.47M-2.39M-3.48M-2.29M-1.78M-2.61M-3.24M-2.59M-2.51M-1.20M-3.81M-2.38M-3.15M-3.09M-2.79M
Interest ExpensesInt Expense
0.01M0.07M0.11M0.01M
Tax Rate
2.37%